The Economic Burden of Campylobacter-Associated Guillain-Barré Syndrome

Guillain-Barré syndrome (GBS) is an autoimmune disease characterized by acute neuromuscular paralysis. Of an estimated annual number of 2628–9575 US cases, 526–3830 are triggered by Campylobacter infection. Research objectives were to identify the lifetime consequences of GBS and, when possible, to...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1997-12, Vol.176 (Supplement-2), p.S192-S197
Main Authors: Buzby, Jean C., Allos, Ban Mishu, Roberts, Tanya
Format: Article
Language:English
Subjects:
Biological and medical sciences
Campylobacter infections
Campylobacter Infections - complications
Campylobacter Infections - economics
Capital costs
Cost estimates
Cost of Illness
Diseases
Economic costs
Guillain Barre syndrome
Health Care Costs
Hospital rooms
Humans
Implications of Findings for Campylobacter Vaccine Development and Estimates for Economic Impact
Incidence
Intensive care units
Medical sciences
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Polyradiculoneuropathy - economics
Polyradiculoneuropathy - epidemiology
Polyradiculoneuropathy - etiology
Polyradiculoneuropathy - psychology
Productivity
Respiration, Artificial - economics
United States - epidemiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Guillain-Barré syndrome (GBS) is an autoimmune disease characterized by acute neuromuscular paralysis. Of an estimated annual number of 2628–9575 US cases, 526–3830 are triggered by Campylobacter infection. Research objectives were to identify the lifetime consequences of GBS and, when possible, to quantify their economic burden. The cost-of-illness method was used to calculate annual societal resources spent on medical care and lost productivity due to illness or premature death from Campylobacter-associated GBS. Estimated total costs (in US$) of Campylobacter-associated GBS ($0.2–$1.8 billion) were added to previously estimated costs of campylobacteriosis ($1.3– $6.2 billion) for a total annual cost from Campylobacter of $1.5–$8.0 billion (1995 dollars). It is concluded that up to $8.0 billion in US human illness costs are spent annually because of Campylobacter infection. Economic evaluation of the other costs associated with GBS, such as physical and psychological costs, would increase these estimates.
ISSN:0022-1899
1537-6613
DOI:10.1086/513785